Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol vs Febuxostat in CKD with Hyperuricemia
NCT07850713Active, not recruiting
- Sponsor
- Nishtar Medical University
- Start
- May 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Randomised trial of febuxostat in hyperuricemia (2 arms), sponsored by Nishtar Medical University. Primary endpoint: Percentage of Participants Achieving Serum Uric Acid Below 6.0 mg/dL at 8 weeks. Started May 2026; status: active, not recruiting.
02
Drugs
febuxostat
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT07850713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07850713.